Navigation Links
Epizyme, Inc. Provides Third Quarter 2013 Financial Results and Corporate Update
Date:10/22/2013

his Phase 1 dose escalation study is ongoing and no dose-limiting toxicities have been observed to date."

"Looking ahead to 2014, we plan to pursue additional clinical studies for both candidates in genetically defined cancers beyond the primary indications, including MLL-PTD for EPZ-5676 and synovial sarcoma and other INI1-deficient tumors for EPZ-6438," said Gould. "We are in a strong position to invest in Epizyme's internally generated pipeline and look forward to continued progress with multiple proof of concept studies in 2014."

EPZ-5676 Clinical Development – Progress and Plans

  • Top-line Dose Escalation Data Expected in Fourth Quarter of 2013: The dose escalation stage of the ongoing Phase 1 study of EPZ-5676 is nearing completion, and Epizyme plans to disclose top-line dose escalation data in the fourth quarter of 2013.
  • Clinical Sites Added: Five clinical sites have been added this year, bringing the total number of clinical sites participating in this study to six.
  • Granted Orphan Drug Designation: EPZ-5676 was granted orphan drug designation by the U.S. FDA in August 2013.
  • MLL-r Restricted Expansion Cohort Stage to Begin in Fourth Quarter of 2013: Based on data from the dose escalation stage, Epizyme plans to initiate the expansion cohort stage of the ongoing Phase 1 study in the fourth quarter of 2013. The expansion cohort will be limited to patients with MLL-r and is expected to provide an initial assessment of therapeutic effect in MLL-r patients in 2014. It will include as many as 12 sites in both the United States and Europe. Abbott Molecular Inc., under its collaboration with Epizyme, is developing a molecular companion diagnostic to identify eligible MLL-r patients for EPZ-5676, and the Investigational Use Only (IUO) diagnostic will be available for use in the expansion cohort.
  • Initiation of Pediatric MLL-r Phase 1 Study i
    '/>"/>

  • SOURCE Epizyme, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Epizyme, Inc. Reports Second Quarter 2013 Financial Results
    2. New Resource Provides Herb Industry With Sources of Quality Specifications
    3. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
    4. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
    5. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
    6. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
    7. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
    8. Insmed Incorporated Provides Corporate Update
    9. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
    10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
    11. Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... ®, provider of RapidResponse ®, a cloud-based supply chain ... S&OP ) service, is proud to be a gold sponsor ... at the Hilton San Diego Bayfront, January 30 – 31, ... , Director of Supply Chain at Amgen, as she presents ...
    (Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, ... dual arch impressions on its dental blog. , ... entry serves up a list of tips to help dentists ... Dr. David Little as he crafts a porcelain crown using ...
    (Date:1/14/2014)... 14, 2014 Independent publisher Bitingduck Press, ... Montreal, Canada, has big ideas for 2014 in production ... goals are to produce high-quality, low-cost, DRM-free ebooks and ... businesses. , The first major development will be ...
    (Date:1/14/2014)... MO (PRWEB) January 14, 2014 Holloway ... comprehensive database of material test reports (MTRs) for all ... fabricates. Documenting test results is particularly important for equipment ... regulations. The MTR Library features search functionality that allows ...
    Breaking Biology Technology:Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
    ... ... U.S. House Science and Technology Committee , ... Washington (Vocus) January 27, 2010 -- DuPont Applied BioSciences Vice ... Representatives Science and Technology Committee that the U.S. Department of Energy (DOE) Advanced Research ...
    ... , CAMBRIDGE, Mass. and OXFORD, England ... Institute and Oxford BioMedica (LSE: OXB) announced today the extension ... The extended collaboration, which is funded by the Muscular Dystrophy ... gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies ...
    ... , , WILMINGTON, Del. , Jan. ... fourth quarter 2009 earnings news release contained an extra comma ... following statement: "Due to strong pension fund performance, the company ... per share, lower than originally anticipated."  The foregoing statement should ...
    Cached Biology Technology:DuPont Science Leader Urges U.S. House Committee to Continue Federal Investment in Transformative, Clean Energy Technologies 2ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis 2ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis 3ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis 4ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis 5
    (Date:7/10/2014)... a whole fresh avocado with either an orange-colored tomato ... (alpha- and beta-carotene) absorption and conversion of these carotenoids ... new research (1) published in The Journal ... is involved in reproductive health and growth promotion; helps ... antioxidant properties. Provitamin A carotenoids, like alpha- and beta-carotene, ...
    (Date:7/9/2014)... PA, July 10, 2014 Inflammatory diseases can ... patient, complicating treatment because a medication effective for ... example is the anti-arthritic medication dexamethasone, which alleviates ... A study in the August issue of ... effects of a new class of anti-arthritic drugs, ...
    (Date:7/9/2014)... to switch out one gene for another in a ... science fiction to reality within this decade. As with ... hope of fixing disease-causing genes in humans, for example--as ... have put one of those concerns to rest: using ... occurrence of mutations in the cells. The new results ...
    Breaking Biology News(10 mins):New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2New class of anti-arthritis drugs effectively treats multiple inflammatory diseases 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3
    ... CINCINNATI An experimental procedure successfully tested in obese ... weight-loss surgery, researchers report online in Endocrinology . ... used a catheter to re-direct the flow of bile ... the same metabolic and weight-loss benefits as bariatric surgeries ...
    ... In a comparison of the effect of different dosages ... raised and maintained plasma concentrations within a range recommended ... maintained plasma concentrations within a lower range recommended by ... the May 1 issue of JAMA , a ...
    ... methanol to formaldehyde - this reaction is the starting ... catalysts made of gold particles, formaldehyde could be produced ... Just how the mysterious gold catalyst works has been ... Ruhr-Universitt Bochum in a cooperation project. In the international ...
    Cached Biology News:Study finds possible alternative to bariatric weight loss surgery 2Optimal vitamin D dosage for infants uncertain 2Optimal vitamin D dosage for infants uncertain 3Mysterious catalyst explained 2
    5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
    ...
    All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
    ...
    Biology Products: